Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Uncategorized

Zenvia Postpones IPO

-Dow Jones

byBenzinga Newsdesk

May 13, 2021

1 minute read

-Dow Jones

Mirum Pharmaceuticals Announces CHMP Opinion For LIVMARL Oral Solution For Cholestatic Pruritus In Patients With Alagille Syndrome Two Months Of Age And Older

By Benzinga Newsdesk

October 14, 8:07 AM

- CHMP opinion based on pivotal ICONIC study with more than five years of data demonstrating durable and clinically meaningful improvements in cholestatic pruritus and serum bile acids for patients with Alagille syndrome

MIRM

Needham Maintains Buy on Fiverr International, Lowers Price Target to $100

By Benzinga Newsdesk

February 18, 7:35 AM

Needham analyst Bernie McTernan maintains Fiverr International (NYSE:FVRR) with a Buy and lowers the price target from $205 to $100.

FVRR

Morgan Stanley Maintains Equal-Weight on Spire, Lowers Price Target to $78

By Benzinga Newsdesk

August 19, 9:42 AM

Morgan Stanley analyst Stephen Byrd maintains Spire (NYSE:SR) with a Equal-Weight and lowers the price target from $79 to $78.

Understanding Gilead Sciences’s Unusual Options Activity

By Benzinga Insights

July 8, 1:16 PM

Gilead Sciences (NASDAQ:GILD) shares experienced unusual options activity on Thursday. The stock price moved down to $67.64 following the option alert.

GILD

Zenvia Postpones IPO

Related Posts

Mirum Pharmaceuticals Announces CHMP Opinion For LIVMARL Oral Solution For Cholestatic Pruritus In Patients With Alagille Syndrome Two Months Of Age And Older

Needham Maintains Buy on Fiverr International, Lowers Price Target to $100

Morgan Stanley Maintains Equal-Weight on Spire, Lowers Price Target to $78

Understanding Gilead Sciences’s Unusual Options Activity